Clinical Rheumatology

, Volume 38, Issue 4, pp 977–988 | Cite as

Efficacy of ω-3 supplementation in patients with psoriasis: a meta-analysis of randomized controlled trials

  • Cain C. T. Clark
  • Mohsen Taghizadeh
  • Mina Nahavandi
  • Sadegh JafarnejadEmail author
Review Article


Several studies have been conducted with the aim of investigating the effect of Omega(ω)-3 on different psoriasis indices including Psoriasis Area and Severity Index (PASI) score, erythema, scaling, itching, area involved, and infiltration. Nevertheless, a pooled analysis of trials that evaluated these variables has not been conducted. Therefore, the aim of this meta-analysis was to assess the efficacy of ω-3 fatty acids in treating patients with psoriasis. We searched through different electronic, references of retrieved articles, and previous related reviews databases up to November 2018. Both combined and stratified analyzes were conducted. A fixed-effects or random effects model was used to assess the mean effect sizes. An eventual 10 studies involving 560 participants were considered as eligible for inclusion in the present meta-analysis. The meta-analysis indicated a significant reduction in PASI score by − 1.58 (95% confidence interval (CI), − 2.24, − 0.92; P < 0.001) in favor of ω-3 polyunsaturated fatty acid (PUFA) group. The random effects model showed a statistically significant beneficial effect of ω-3 PUFA supplementation on reducing erythema by − 1.66 unit and reducing scaling (weighted mean difference (WMD), − 0.69; 95% CI, − 1.26, − 0.13; P = 0.02). Significant improvements in erythema, itching, and scale were observed in the trials which used the higher dosage of ω-3 supplementation. The results of current meta-analysis study support the use of ω-3 PUFA supplementation for the improvement of the evaluated parameters in psoriatic patients. However, well-controlled and randomized studies are needed to confirm the veracity of non-significant and/or equivocal findings.


Meta-analysis Polyunsaturated fatty acids Psoriasis PUFA 


Compliance with ethical standards




  1. 1.
    Guida B, Napoleone A, Trio R, Nastasi A, Balato N, Laccetti R, Cataldi M (2014) Energy-restricted, n-3 polyunsaturated fatty acids-rich diet improves the clinical response to immuno-modulating drugs in obese patients with plaque-type psoriasis: a randomized control clinical trial. Clin Nutr 33(3):399–405CrossRefGoogle Scholar
  2. 2.
    Rahman M, Beg S, Ahmad MZ, Kazmi I, Ahmed A, Rahman Z, Ahmad FJ, Akhter S (2013) Omega–3 fatty acids as pharmacotherapeutics in psoriasis: current status and scope of nanomedicine in its effective delivery. Curr Drug Targets 14(6):708–722CrossRefGoogle Scholar
  3. 3.
    Adil M, Singh PK, Maheshwari K (2017) Clinical evaluation of omega-3 fatty acids in psoriasis. Dermatology Review/Przeglad Dermatologiczny 104(3)Google Scholar
  4. 4.
    Burns T (2010) Rook’s textbook of dermatology. print and online package. Wiley-Blackwell,Google Scholar
  5. 5.
    Upala S, Yong WC, Theparee T, Sanguankeo A (2017) Effect of omega-3 fatty acids on disease severity in patients with psoriasis: a systematic review. Int J Rheum Dis 20(4):442–450CrossRefGoogle Scholar
  6. 6.
    Qin S, Wen J, Bai X-C, Chen T-Y, Zheng R-C, Zhou GB, Ma J, Feng J-Y, Zhong B-L, Li Y-M (2014) Endogenous n-3 polyunsaturated fatty acids protect against imiquimod-induced psoriasis-like inflammation via the IL-17/IL-23 axis. Mol Med Rep 9(6):2097–2104CrossRefGoogle Scholar
  7. 7.
    Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269 w264CrossRefGoogle Scholar
  8. 8.
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12CrossRefGoogle Scholar
  9. 9.
    Gopalakrishnan S, Ganeshkumar P (2013) Systematic reviews and meta-analysis: understanding the best evidence in primary healthcare. J Family Med Prim Care 2(1):9–14. CrossRefGoogle Scholar
  10. 10.
    Balbás GM, Regaña MS, Millet PU (2011) Study on the use of omega-3 fatty acids as a therapeutic supplement in treatment of psoriasis. Clin Cosmet Investig Dermatol 4:73CrossRefGoogle Scholar
  11. 11.
    Bittiner S, Cartwright I, Tucker W, Bleehen S (1988) A double-blind, randomised, placebo-controlled trial of fish oil in psoriasis. Lancet 331(8582):378–380CrossRefGoogle Scholar
  12. 12.
    Bjørneboe A, Smith AK, Bjørneboe GEA, Thune P, Drevon C (1988) Effect of dietary supplementation with n-3 fatty acids on clinical manifestations of psoriasis. Br J Dermatol 118(1):77–83CrossRefGoogle Scholar
  13. 13.
    Escobar S, Achenbach R, Iannantuono R, Torem V (1992) Topical fish oil in psoriasis—a controlled and blind study. Clin Exp Dermatol 17(3):159–162CrossRefGoogle Scholar
  14. 14.
    Grimminger F, Mayser P, Papavassilis C, Thomas M, Schlotzer E, Heuer K-U, Führer D, Hinsch K-D, Walmrath D, Schill W-B (1993) A double-blind, randomized, placebo-controlled trial of n-3 fatty acid based lipid infusion in acute, extended guttate psoriasis. Clin Investig 71(8):634–643CrossRefGoogle Scholar
  15. 15.
    Gupta A, Ellis C, Tellner D, Anderson T, Voorhees JJ (1989) Double-blind, placebo-controlled study to evaluate the efficacy of fish oil and low-dose UVB in the treatment of psoriasis. Br J Dermatol 120(6):801–807CrossRefGoogle Scholar
  16. 16.
    Soyland E, Funk J, Rajka G, Sandberg M, Thune P, Rustad L, Helland S, Middelfart K, Odu S, Falk ES (1993) Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis. N Engl J Med 328(25):1812–1816CrossRefGoogle Scholar
  17. 17.
    Veale D, Torley H, Richards I, O’DOWD A, Fttzsimons C, Belch J, Sturrock R (1994) A double-blind placebo controlled trial of Efamol Marine on skin and joint symptoms of psoriatic arthritis. Rheumatology 33(10):954–958CrossRefGoogle Scholar
  18. 18.
    Mori T, Kondo H, Hase T, Tokimitsu I, Murase T (2007) Dietary fish oil upregulates intestinal lipid metabolism and reduces body weight gain in C57BL/6J mice. J Nutr 137(12):2629–2634CrossRefGoogle Scholar
  19. 19.
    Spuls PI, Lecluse LL, Poulsen M-LN, Bos JD, Stern RS, Nijsten T (2010) How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Investig Dermatol 130(4):933–943CrossRefGoogle Scholar
  20. 20.
    Sterne JA, Egger M (2001) Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54(10):1046–1055CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2019

Authors and Affiliations

  • Cain C. T. Clark
    • 1
  • Mohsen Taghizadeh
    • 2
  • Mina Nahavandi
    • 2
  • Sadegh Jafarnejad
    • 2
    Email author
  1. 1.Faculty of Health and Life SciencesCoventry UniversityCoventryUK
  2. 2.Research Center for Biochemistry and Nutrition in Metabolic DiseasesKashan University of Medical SciencesKashanIran

Personalised recommendations